[L-acetylcarnitine treatment on fragile X patients hyperactive behaviour]
M Calvani1, S D'Iddio, A de Gaetano
1Departamento Científico, Sigma-Tau S.p.A., Rome, Italy.
Abstract:
Hyperactivity is a significant problem for almost all young males affected by fragile X syndrome (FXS), the most common inherited disease causing mental retardation. Therapeutical approaches are actually based on Central Nervous System (CNS) stimulants lacking a well defined rationale and efficacy while they further decrease the patient's limited attention span. A pilot study on 17 fragile X male treated with L-acetylcarnitine (LAC) over one year, showed a significant reduction of their hyperactivity behaviour tested by the Conners Abbreviated Parent-Teacher Questionnaire. LAC use in FXS patients derives from the hypothesis that the biochemical and physiological properties this substance has may preserve brain activity. LAC is a small, hydrosoluble molecule that easily diffuses in the extracellular space and enters any cell in the nervous system through specific transporters. Different cerebral areas use this molecule differently to metabolize glucose and lipids to provide for ATP and neurotrasmitters synthesis. The acetyl group LAC carriers represents a key metabolic signaling element possibly mediating its effect in the CNS. The exogenous administration of LAC may affect brain activity in FXS by: I) modulation of fuel partitioning for energy production, which at the mithocondrial level is associated with the Kreb's cycle metabolic role in neurotransmitter synthesis; II) remodelling of lipid membrane in terms of LAC actively determining the production of polyunsaturated fatty acids; III) preferential effect on the attention component of the cholinergic system which relies on its peculiar modality of communication in the CNS. Based on the above premises an explorative, double-blind, placebo controlled, multicenter study is ongoing. A total population of 160 children from nine European centers will be enrolled. The objective of this study is to determine the effect of LAC on the hyperactive behaviour of FXS children as evaluated by the administration of the Conners Abbreviated Parent Questionnaire.
Insights
L-acetylcarnitine (LAC) significantly reduced hyperactivity in young males with fragile X syndrome (FXS). This pilot study suggests LAC may improve brain function and attention in FXS patients.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability, with hyperactivity affecting nearly all young males.
- Current treatments for FXS hyperactivity, such as CNS stimulants, often lack efficacy and can worsen attention deficits.
Purpose of the Study:
- To investigate the potential of L-acetylcarnitine (LAC) as a therapeutic agent for hyperactivity in males with FXS.
- To evaluate the impact of LAC on brain activity, energy metabolism, and neurotransmitter synthesis in FXS.
Main Methods:
- A pilot study involved 17 males with FXS treated with LAC for one year.
- Hyperactivity was assessed using the Conners Abbreviated Parent-Teacher Questionnaire.
- An ongoing multicenter, double-blind, placebo-controlled study will enroll 160 children with FXS.
Main Results:
- The pilot study demonstrated a significant reduction in hyperactivity behaviors in FXS males treated with LAC.
- LAC's proposed mechanisms include modulating energy production, remodeling lipid membranes, and affecting the cholinergic system.
Conclusions:
- L-acetylcarnitine shows promise in reducing hyperactivity in fragile X syndrome.
- Further research through a larger, controlled trial is warranted to confirm LAC's efficacy and safety in FXS.
More Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
Related Concept Videos
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Huntington Disease l: Introduction
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
